ERBB2 and ductal breast carcinoma in situ: Efforts in biomarker development and testing for additional markers such as HER2 in DCIS for risk stratification18,37–39, combined with evidence for the use of more tolerable endocrine therapies for both invasive breast cancer and DCIS40–42 should help refine treatment approaches.